Fig. 5
From: The novel TRPA1 antagonist BI01305834 inhibits ovalbumin-induced bronchoconstriction in guinea pigs
Effect of TRPA1 antagonist (1 mg.kg−1 BI01305834) on allergen-induced changes in airway hyperresponsiveness (AHR) and magnitude of the early (EAR) and late asthmatic reaction (LAR). AHR in response to histamine is assessed 6 h after ovalbumin exposure, directly after the EAR (a), and 24 h after allergen exposure, directly after the LAR (b). Furthermore, the magnitude of the EAR (c) and LAR (d) were assessed, by calculating the area under the curve (AUC) of the pleural pressure data. *P < 0.05 compared to saline-challenged; vehicle-treated (Kruskal–Wallis ANOVA on ranks followed by Dunnett’s post hoc test), *P < 0.05 (Mann–Whitney U test). (Veh/Sal = 7 animals, Veh/OA = 11 animals, BI/Sal = 7 animals, BI/OA = 13 animals)